Caris Life Sciences, Inc. Common Stock vs. GRAIL, Inc. Common Stock
CAI
Caris Life Sciences, Inc. Common Stock
$31.75 -0.72%
VS GRALGRAIL, Inc. Common Stock
$136.57 +2.97%
Caris Life Sciences, Inc. Common Stock (CAI) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| CAI | GRAL | |
|---|---|---|
| Market Cap | $8.97 billion | $5.92 billion |
| Revenue (TTM) | $989.61 million | $165.26 million |
| Net Income (TTM) | $105.14 million | $-391,587,000 |
CAI leads on 3 of 3 size & scale factors.
Valuation
| CAI | GRAL | |
|---|---|---|
| P/E Ratio | 18.79 | — |
| Price / Book | 15.16 | 2.33 |
| Price / Sales | 9.07 | 35.85 |
CAI and GRAL split the valuation factors evenly.
Profitability
| CAI | GRAL | |
|---|---|---|
| Net Margin | 10.62% | -236.95% |
| Return on Equity | 17.77% | -15.40% |
CAI leads on 2 of 2 profitability factors.
Dividend
| CAI | GRAL | |
|---|---|---|
| Dividend Yield | 3.78% | — |
| Payout Ratio | 71.01 | — |
CAI and GRAL split the dividend factors evenly.
Risk & Sentiment
| CAI | GRAL | |
|---|---|---|
| Short Interest | 0.13% | 5.12% |
CAI leads on 1 of 1 risk & sentiment factors.
Dig deeper: CAI overview, CAI financials, GRAL overview, GRAL financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.